Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial

NCT01641783 is registered in ClinicalTrials.gov with Yanqiao Zhang as lead sponsor.

NCT NCT01641783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01641783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial
Lead sponsor
Yanqiao Zhang
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2012
Completion date
December 31, 2013
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma